Conclusion
This study compared reoperation rates of CE Perimount and SJM Trifecta aortic bioprostheses for AVR. The rates of reoperation were comparable, with Trifecta showing higher rates in patients younger than 60 years, and current smokers. Literature has also shown that reoperation rates of Trifecta are comparable to Perimount valves, with a few recent studies bringing into focus early SVD in Trifecta, and increased midterm SVD in younger patients. Continued diligence and further independent reporting of midterm reoperation and SVD rates of the Trifecta, including detailed echocardiographic follow up, are needed to confirm these findings.